S-1/A: Shoulder Innovations Files S-1/A for IPO, Reveals Strong Revenue Growth Amid Rising Losses and New Capital Infusion

Shoulder Innovations, a medical technology company focused on shoulder surgical care, filed an S-1/A for its initial public offering, showcasing significant revenue growth but also increasing net losses and detailing a recent $40 million convertible note financing.

Summary

• Shoulder Innovations is a commercial-stage medical technology company specializing in shoulder surgical care, offering advanced implant systems for shoulder arthroplasty.
• The company's ecosystem includes advanced implant systems (aTSA and rTSA), ProVoyance preoperative planning technology (AI/ML-enabled), and an efficient two-tray instrument system.
• Net revenue grew by 64.0% year-over-year to $31.6 million for the year ended December 31, 2024, up from $19.3 million in 2023.
• For the three months ended March 31, 2025, net revenue increased by 41.0% to $10.1 million, compared to $7.2 million for the same period in 2024.
• Net loss increased to $15.6 million for the year ended December 31, 2024, from $12.7 million in 2023.
• Net loss for the three months ended March 31, 2025, was $4.7 million, compared to $3.6 million for the same period in 2024.
• Adjusted EBITDA loss increased to $11.4 million for 2024 from $8.7 million in 2023, and to $3.5 million for Q1 2025 from $2.6 million for Q1 2024.
• The company issued $40.0 million in convertible promissory notes on July 18, 2025, which will automatically convert into common stock upon IPO completion.
• Preliminary estimated financial results for Q2 2025 project net revenue between $10.8 million and $11.2 million, and net loss between $19.1 million and $21.1 million, significantly higher than Q2 2024 due to non-cash charges.
• The company's InSet Glenoid technology has demonstrated strong clinical results, including a 72-point improvement in ASES outcome score and no glenoid loosening or revision surgeries at a mean 8.7-year follow-up in one study.
• Approximately 30% of procedures using the company's implant systems in December 2024 were performed in Ambulatory Surgery Centers (ASCs), up from 10% in December 2023, outpacing overall ASC shoulder arthroplasty growth.
• The company has been approved to list its common stock on the New York Stock Exchange under the symbol SI.
• The initial public offering is for 5,000,000 shares of common stock, with an anticipated price range of $19.00 to $21.00 per share.

Sentiment

Score: 6

Explanation: The company demonstrates strong revenue growth and a compelling product ecosystem with positive clinical data and market positioning in a growing sector (ASCs). However, significant and increasing net losses, high debt, and reliance on single-source suppliers present substantial financial and operational risks. The recent capital raise addresses immediate funding needs but highlights ongoing capital intensity. The preliminary Q2 2025 results show a significantly higher net loss, albeit due to non-cash charges, which still impacts the bottom line.

Positives

• Experienced significant net revenue growth, with 64.0% year-over-year growth in 2024 and 41.0% growth in Q1 2025.
• Implied utilization rate for ProVoyance preoperative planning technology was approximately 98% for the three months ended June 30, 2025, indicating strong surgeon adoption.
• Strong clinical evidence supports the safety, efficacy, and durability of InSet Glenoid technology, with a published study showing a 72-point improvement in ASES outcome score and no glenoid loosening or revision surgeries at 8.7 years.
• Well-positioned to capitalize on the growth of outpatient and ASC settings, with ASC-based procedures using its systems increasing by approximately 350% from 2023 to 2024.
• Proprietary two-tray instrument system designed for efficiency, reducing operating room footprint, setup time, and sterilization costs.
• Robust product pipeline includes anticipated expansion of humeral stem line, indication expansions into fracture and revision, and implants for metal-sensitive patients.
• Management team has decades of experience in orthopedic product development and commercialization, holding over 250 combined orthopedic patents.
• AI-enabled business and clinical intelligence technologies, including ProVoyance, support surgeon targeting, patient acquisition, and outcomes measurement.

Negatives

• History of significant net losses, with $15.6 million in 2024 and $4.7 million in Q1 2025, and expects to incur additional substantial losses in the foreseeable future.
• Accumulated deficit of $61.7 million as of March 31, 2025.
• Preliminary estimated net loss for Q2 2025 is significantly higher, ranging from $19.1 million to $21.1 million, compared to $4.2 million in Q2 2024, primarily due to non-cash charges.
• Adjusted EBITDA loss increased to $11.4 million in 2024 and is projected to be between $18.0 million and $20.0 million for Q2 2025.
• Has a significant amount of debt, with $15.0 million principal outstanding under the Trinity Loan Agreement as of March 31, 2025.
• Gross margin decreased slightly to 77.0% in 2024 from 79.2% in 2023, primarily due to inventory adjustments.
• Selling, general and administrative expenses increased significantly by 49% in 2024 and 36.3% in Q1 2025, driven by increased headcount, legal costs, commissions, and depreciation.
• Research and development expenses increased by 49% in 2024 and 48% in Q1 2025 due to new product development efforts and external consulting fees.

Risks

• History of significant net losses and expectation of future operating losses, with no assurance of achieving or sustaining profitability.
• Failure to manage rapid growth effectively could materially and adversely affect the business.
• Significant amount of debt ($15.0 million outstanding as of March 31, 2025) may affect ability to operate and secure additional financing, with covenants that could lead to default.
• May require substantial additional funding, which may not be available on acceptable terms or at all, potentially delaying or ceasing innovation efforts or operations.
• Operates in a very competitive business environment with larger, more resourced competitors, potentially affecting market share and profitability.
• Dependence on the adoption of implant systems by hospitals, ASCs, surgeons, and patients, which may be slow due to various factors.
• Long-term growth depends on ability to enhance implant systems, expand indications, and commercialize additional products in a timely manner; failure to innovate could lead to obsolescence.
• Risk of product liability claims that could be expensive, divert management attention, and harm reputation, with no guarantee of adequate insurance coverage.
• Industry trends toward downward pricing pressure on medical services and products may affect ability to sell products at necessary prices.
• Reliance on third-party contract manufacturers and suppliers, some of which are single-source, posing risks of supply shortages, quality issues, and regulatory non-compliance.
• Inability to accurately forecast demand and manage inventory could materially harm results of operations.
• Difficulty in continuing to successfully demonstrate the merits of implant systems to shoulder specialists or key opinion leaders compared to competitors.
• Loss of any member of the executive management team or inability to attract and retain highly skilled personnel could have a material adverse effect.
• Inability to obtain and maintain significant patent or other intellectual property protection, or if the scope of IP rights is inadequate, competitors could commercialize similar products.
• Devices and operations are subject to extensive government regulation and oversight; failure to comply could harm business.
• Relationships with customers, physicians, and third-party payors are subject to federal and state health care fraud and abuse laws, false claims laws, and physician payment transparency laws; violations could lead to substantial penalties.
• AI solutions present risks such as inaccuracy, bias, toxicity, intellectual property infringement, data privacy, and cybersecurity, with an evolving regulatory framework.
• Inability to establish or strengthen brand could adversely affect business.
• Inability to maintain contractual relationships with healthcare professionals could negatively impact R&D and medical education programs.
• Future international expansion will subject the company to additional costs and risks.
• Subject to claims of misappropriation of third-party intellectual property, including trade secrets or know-how.
• Patent terms may not be sufficient to effectively protect systems for an adequate period.
• Changes in U.S. or foreign patent laws or their interpretation may limit ability to obtain, maintain, defend, and/or enforce patents.
• Third-party manufacturing partners may not respect intellectual property and trade secrets, potentially producing competitive products.
• Use of open source software could impose limitations on ability to commercialize products.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Adverse effects from natural disasters and other catastrophic events on operations or supply chain.
• Subject to legal and arbitration proceedings that may prevent business activities or incur additional costs.
• Requirements of being a public company may divert management's attention and increase costs.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Insurance may not cover all potential losses or liabilities.
• Subject to U.S. anti-bribery, anti-corruption, and anti-money laundering laws, as well as export control and economic sanctions.
• Changes in tax laws or regulations or their interpretation may seriously harm business.
• Increasing use of social media platforms presents new risks and challenges.
• Could be subject to securities class action litigation.

Future Outlook

The company plans to leverage its ecosystem to become a leader in shoulder surgical care, focusing on increasing market awareness and adoption across care settings, expanding its commercial organization, and capitalizing on ASC growth. It intends to continue significant investments in product development, including fracture-specific systems, revision solutions, and implants for metal-sensitive patients, and is evaluating expansion into sports medicine and shoulder trauma markets. The company also plans to further build and market its AI-enabled technology solutions and pursue strategic entry into international markets.

Management Comments

• Management believes their exclusive focus on shoulder surgical care, combined with a highly specialized commercial organization and strong clinical data, positions them well to capture significant share in this large, growing market.
• Management believes the differentiation and value proposition of ProVoyance is validated by high utilization rates across procedures using their advanced implant systems.
• Management believes their efficient, two-tray instrument system can enable surgeons and staff to reduce operating room footprint, procedural setup time, sterilization time and expense, and procedural complexity.
• Management attributes success to a disruptive ecosystem, strong clinical results, positioning in outpatient settings, a proven management team, a unique commercial organization, and AI-enabled technologies.
• Management believes that surgeon-level engagement in preoperative planning provides for better care for patients, and that bespoke surgical plans can help facilitate consistent positioning of implants.
• Management believes their commitment to continuous innovation will further expand their addressable market opportunity and improve their competitive position in shoulder surgical care.
• Management believes their commercial flywheel and exclusive focus on shoulder care allow them to convert high-potential accounts and nurture new surgeons into loyal users of their ecosystem.
• Management views digital enablement as an essential component of modern shoulder surgical care and believes that their technologies can drive greater clinical value and deepen physician engagement.

Industry Context

The shoulder surgical care market is large and growing, driven by an aging population, increasingly active lifestyles, and greater awareness of treatment options. There's a historical underutilization of surgical treatments due to patient hesitation, insufficient technology, and perceived surgical difficulty. The market is experiencing a significant shift towards outpatient settings, particularly Ambulatory Surgery Centers (ASCs), due to lower costs and increased efficiency. The company's focus on a specialized ecosystem, including AI-enabled planning and efficient instrumentation, aims to address limitations of traditional implants and capitalize on the ASC growth trend, similar to what has occurred in hip and knee arthroplasty markets. The industry is highly competitive with large multinational players and smaller innovators.

Comparison to Industry Standards

• The company's two-tray instrument system is considerably less than the six to nine trays typically required by other offerings in shoulder arthroplasty, providing significant workflow advantages and cost reduction for healthcare providers, especially in ASCs.
• The company's InSet Glenoid technology aims to reduce mechanical stress and micromotion, which are key contributors to glenoid loosening, a primary problem in legacy aTSA implants, with a published study demonstrating an 87% reduction in rocking horse motion compared to standard onlay designs.
• The company's rTSA system is designed to optimize biomechanics to function more like an anatomic implant, aiming to avoid arm lengthening and overstuffing common with traditional rTSA implants.
• The company's ProVoyance preoperative planning technology is highly differentiated from other solutions where third-parties create surgical plans, as it empowers surgeons to independently create bespoke plans, leading to high utilization rates (98% implied utilization in Q2 2025).
• The company's ASC-based procedures increased approximately 350% from 2023 to 2024, significantly outpacing the approximately 26% growth in ASC-based shoulder arthroplasty procedures in the United States over the same period, indicating strong market penetration in this high-growth segment.
• The company's management team has a combined 250+ orthopedic patents, reflecting deep clinical insight and technical expertise, which is a competitive advantage in the medical technology industry.

Management Changes

Corporate Governance

Legal Proceedings

• Filed a complaint against Catalyst OrthoScience Inc. on February 28, 2024, in the United States District Court for the District of Delaware (Case No. 1:24-cv-00266-JPM), alleging patent infringement related to Catalyst's reverse shoulder systems.
• Catalyst OrthoScience Inc. filed a counterclaim alleging patent infringement of its patent based on certain of the company's products.
• The company believes it has substantial and meritorious defenses to Catalyst's counterclaim and intends to vigorously defend its position.

Related Party Transactions

• Robert Ball (CEO & Executive Chairman) is a co-founder and director of Genesis Innovation Group, Inc. and Genesis Software Innovations, LLC.
• Matthew Ahearn (COO & Director) is a director of Genesis Investment Holdings, LLC, which has an ownership interest in Genesis Software, and is also a director of cultivate(MD) Holdings, LLC.
• David L. Blue (Chief Customer Experience Officer) is a director of cultivate(MD) Capital Funds and cultivate(MD) Holdings, LLC.
• Entities affiliated with cultivate(MD) (a beneficial owner of more than 5% of capital stock) are investors in Genesis Software.
• Paid Genesis Innovation Group $3.6 million in 2024 and $2.8 million in 2023 for consulting services (concept development, IP creation, surgeon relationship management, project management).
• Paid Genesis Innovation Group $1.2 million for consulting services in Q1 2025.
• Paid Genesis Software $3.1 million in 2024 and $3.2 million in 2023 pursuant to a software license agreement, including royalties of $1.2 million and $0.6 million respectively.
• Paid Genesis Software $0.9 million in Q1 2025 pursuant to the software license agreement, including royalties of $0.3 million.
• Paid RMD $0.9 million in 2024 and $2.3 million in 2023 for manufacturing surgical instruments; Robert Ball was an investor in RMD during these periods but is no longer an investor as of the filing date.
• Certain directors and officers (Robert Ball, Matthew Ahearn, David L. Blue, Michael Carusi, Geoff Pardo, Casey Tansey) are associated with principal stockholders (cultivate(MD), Lightstone Ventures, U.S. Venture Partners, Coperatieve Gilde Healthcare V U.A.).
• The company's Fourth Amended and Restated Investor Rights Agreement, Voting Agreement, and Right of First Refusal and Co-Sale Agreement involve holders of preferred stock, including entities affiliated with certain directors, and will terminate upon IPO completion.
• The company has entered into indemnification agreements with each of its directors and executive officers.

Stakeholder Impact

• **Shareholders**: Potential for dilution from the IPO and future equity issuances. Existing shareholders will experience immediate and substantial dilution. The market price of common stock may be volatile. Voting power of principal stockholders and management will remain significant (approximately 57.1% post-IPO).
• **Employees**: Participation in a directed share program for the IPO. Eligible for new 2025 Incentive Award Plan and 2025 Employee Stock Purchase Plan, providing equity ownership opportunities. Increased headcount expected in commercial organization.
• **Customers (Hospitals, ASCs, Surgeons)**: Continued focus on providing advanced implant systems, preoperative planning technology (ProVoyance), and efficient instrument systems. Enhanced specialized support and surgeon-to-surgeon collaboration. Potential for improved patient outcomes and procedural efficiency.
• **Suppliers**: Continued reliance on third-party contract manufacturers and suppliers, some of which are single-source, creating supply chain risks.
• **Creditors**: Existing debt obligations under the Trinity Loan Agreement ($15.0 million outstanding) and new 2025 Convertible Notes ($40.0 million) will impact cash flow for interest and principal payments. Obligations are collateralized by substantially all assets.

Next Steps

• Complete the initial public offering of 5,000,000 shares of common stock on the New York Stock Exchange under the trading symbol SI.
• Scale up commercial organization through hiring additional sales representatives and expanding the commercial leadership team.
• Invest in additional instrument sets to support volume growth and geographic expansion.
• Fund research and development for continued general innovation in implant systems.
• Pursue FDA clearance for InSet 70, InSet 135, and InSet 185 stems over the next twelve months.
• Pursue FDA clearance for humeral head and glenoid technologies for metal-sensitive patients over the next twelve months.
• Evaluate expansion into adjacent areas in shoulder surgical care, including sports medicine and shoulder trauma markets.
• Assess the implementation of robotic-assisted technology for implant systems.
• Expect the first publication of the patient registry data as early as 2026.
• Comply with public company reporting requirements, Sarbanes-Oxley Act, and New York Stock Exchange rules.

Key Dates

Recommendation

Shoulder Innovations demonstrates impressive revenue growth and a strong market position in the rapidly expanding shoulder arthroplasty and ASC segments. Its innovative product ecosystem, backed by clinical data and an experienced management team, presents a compelling long-term growth story. However, the company has a history of significant and increasing net losses, substantial debt, and relies heavily on single-source suppliers, which introduces considerable risk. While the recent capital raise provides necessary liquidity for growth initiatives, the path to profitability remains unclear. For a seasoned investor, the current financial profile suggests a 'Hold' position, awaiting clearer trends in profitability and successful execution of its growth strategies post-IPO, particularly how it manages escalating operating expenses and non-cash charges impacting net income.

Keywords

Shoulder arthroplasty, Medical devices, Orthopedics, Surgical implants, InSet Glenoid, ProVoyance, AI-enabled medical devices, Reverse total shoulder arthroplasty, Anatomic total shoulder arthroplasty, Ambulatory Surgery Centers (ASCs), Healthcare technology, Medical technology, IPO, SEC filing, S-1/A, Biomedical engineering, Orthopedic surgery, Implant systems, AI/ML in healthcare, Medical device regulation